S81125 |
TG101348 (SAR302503) |
源葉(MedMol) | 98% |
- 提示:詳情請(qǐng)下載說明書。
- 產(chǎn)品描述: Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research
- 靶點(diǎn): JAK2:3 nM (IC50);JAK2(V617F):3 nM (IC50);Flt3:15 nM (IC50);Ret:48 nM (IC50);Apoptosis;?FLT;?c-RET;?JAK
- 體內(nèi)研究:
Fedratinib (TG101348; 60-120 mg/kg; oral gavage; twice daily; for 42 days; C57Bl/6 mice) trewatment shows a dose-dependent reduction in polycythemia and a marked dose-dependent reduction in splenomegaly of treated animals
- 參考文獻(xiàn):
1. Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. 2. Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30.
- 溶解性: DMSO : 125 mg/mL (238.24 mM; Need ultrasonic)
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.906 ml 9.53 ml 19.059 ml 5 mM 0.381 ml 1.906 ml 3.812 ml 10 mM 0.191 ml 0.953 ml 1.906 ml 50 mM 0.038 ml 0.191 ml 0.381 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)